Meiji Seika Pharma Co. Ltd.
Division of Meiji Holdings Co. Ltd.
www.meiji-seika-pharma.co.jp/english/
Latest From Meiji Seika Pharma Co. Ltd.
Newron STARS Fade With Sarizotan Failure
Sarizotan, licensed from Merck KGaA in 2011 for Rett syndrome, was seen as a potential gamechanger for Newron but the termination of the project leaves a huge hole in the Italian group's pipeline.
Asia Deal Watch: BeiGene Leaps Into New Year By Licensing DKK1 Antibody Candidate
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.
Deal Watch: Pfizer Licenses Skin-Targeted JAK Inhibitor Portfolio From Theravance
Deal with Pfizer makes for Theravance’s third large pharma partnership since 2016. AbbVie off-loads Marinol to India’s Alkem, Bausch licenses candidate for rare form of dry eye disease from Novaliq.
Meiji And Dong-A Start European Ustekinumab Trial
A Phase I study will compare the pharmacokinetics, safety and tolerability of Meiji and Dong-A’s DMB-3115 ustekinumab biosimilar candidate against Janssen’s Stelara reference psoriasis and Crohn’s disease brand.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
- Therapeutic Areas
- Cancer
- Infectious & Viral Diseases
- Neurology, Nervous System
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
Asia
-
Pacific Rim
-
Japan
-
Japan
-
Pacific Rim
-
Asia
- Parent & Subsidiaries
- Meiji Holdings Co. Ltd.
- Senior Management
- Daikichiro Kobayashi, PhD, Pres.
- Contact Info
-
Meiji Seika Pharma Co. Ltd.
Phone: (81) 3-3272-6511
4-16 Kyobashi 2-chome, Chuo-ku
Tokyo , 104-8002
Japan